Shanghai Laishi announced that Nanyue Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has received a “Drug Registration Certificate” for human fibrinogen issued by the State Drug Administration. This medicine is an injection, 0.5 g/bottle, for congenital fibrinogen reduction or deficiency. This approval has enriched the company's product layout, improved the overall utilization rate of plasma, and helped enhance core competitiveness. Nanyue Biotech will accelerate product production arrangements and promote their early listing.

Shanghai Laishi announced that Nanyue Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has received a “Drug Registration Certificate” for human fibrinogen issued by the State Drug Administration. This medicine is an injection, 0.5 g/bottle, for congenital fibrinogen reduction or deficiency. This approval has enriched the company's product layout, improved the overall utilization rate of plasma, and helped enhance core competitiveness. Nanyue Biotech will accelerate product production arrangements and promote their early listing.